nicolas_ Immunome, Inc. ( NASDAQ: IMNM ) is an interesting biotech to consider, and that's because it has various therapy types it deploys for its pipeline. One of the lead assets it has is AL102, which is being explored in the ongoing phase 3 RINGSIDE study for the treatment of patients with desmoid tumors.
Enrollment for Part B of this study was completed back in February 2024 and data from this is expected to be released in the 2nd half of 2025. The truth is that AL102, along with AL101, were two clinical assets acquired from Ayala Pharmaceuticals ( OTCQX:ADXS ). Should phase 3 clinical testing go well for Immunome in advancing the use of AL102 for the treatment of patients with desmoid tumors, then it is highly likely that it might even be in a position to file a New Drug Application [NDA] for this program in 2025 as well.
What may reduce the risk for this biotech is that it is not riding everything on only advancing AL102 forward. It has two other clinical candidates with different modes of action, which are highly sought out for. One of them is an antibody-drug conjugate [ADC] targeting the ROR1 protein for solid tumors known as IM-1021.
The second one is a radioligand therapy [RLT] targeting FAP expressing solid tumors. The point here is that both of such technologies, ADC and RLTs, are highly sought out because of what has been shown with them thus far. Lastly, the company has its very own technology known as the "Immunome Discovery Engine," which has a purpose to ide.
